BOSTON — A unique genetic signature, dubbed SIG4, observed in patients with high-risk TP53-mutated myeloid neoplasms is associated with improved survival outcomes potentially leading to important treatment implications, according to the results of a new study. “Our findings suggest that the SIG4 genetic signature could serve as an important prognostic and potentially predictive biomarker in […]
The post Not All TP53-Mutated Myeloid Neoplasms Are Created Equal first appeared on News Health.
Author : News Health
Publish date : 2025-03-31 09:34:00
Copyright for syndicated content belongs to the linked Source.